Bayer bolsters R&D platform with $2bn Vividion takeoverBayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will Share XBayer bolsters R&D platform with $2bn Vividion takeoverhttps://pharmaphorum.com/news/bayer-bolsters-rd-platform-with-2bn-vividion-takeover/
Bayer buys into Arvinas protein degrader discovery platformBayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new Share XBayer buys into Arvinas protein degrader discovery platformhttps://pharmaphorum.com/news/bayer-buys-into-arvinas-protein-degrader-discovery-platform/
